How to buy NeoGenomics stock (NEO)

NeoGenomics is a diagnostics & research business based in the US. NeoGenomics shares (NEO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $13.48 – an increase of 2.67% over the previous week. NeoGenomics employs 2,100 staff and has a trailing 12-month revenue of around $628.2 million.

Our top picks for where to buy NeoGenomics stock

Buy NeoGenomics stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

NeoGenomics stock price (NASDAQ: NEO)

Use our graph to track the performance of NEO stocks over time.

NeoGenomics shares at a glance

• Key figures

Information last updated 2024-10-23.

Latest market close	$13.48
52-week range	$12.77 - $21.22
50-day moving average more info button	$15.26
200-day moving average more info button	$14.96
Wall St. target price	$20.75
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.62

Is it a good time to buy NeoGenomics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

NeoGenomics price performance over time

Historical closes compared with the close of $13.07 from 2024-10-25

1 week (2024-10-22)	-1.13%
1 month (2024-09-27)	-9.86%
3 months (2024-07-29)	-10.72%
6 months (2024-04-29)	-14.13%

1 year (2023-10-27)	-3.97%
2 years (2022-10-28)	74.50%
3 years (2021-10-29)	46
5 years (2019-10-29)	23.36

Is NeoGenomics stock undervalued or overvalued?

Valuing NeoGenomics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of NeoGenomics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

NeoGenomics's PEG ratio

NeoGenomics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 3.02. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into NeoGenomics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

NeoGenomics financials

Revenue TTM	$628.2 million
Gross profit TTM	$187.9 million
Return on assets TTM	-3.26%
Return on equity TTM	-8.39%
Profit margin	-12.5%
Book value	$7.16
Market Capitalization more info button	$1.7 billion

TTM: trailing 12 months

NeoGenomics share dividends

We're not expecting NeoGenomics to pay a dividend over the next 12 months.

Have NeoGenomics's shares ever split?

NeoGenomics's shares were split on a 1:100 basis on 15 April 2003 . So if you had owned 100 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your NeoGenomics shares – just the quantity. However, indirectly, the new 9900% higher share price could have impacted the market appetite for NeoGenomics shares which in turn could have impacted NeoGenomics's share price.

NeoGenomics share price volatility

Over the last 12 months, NeoGenomics's shares have ranged in value from as little as $12.77 up to $21.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while NeoGenomics's is 1.184. This would suggest that NeoGenomics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).

NeoGenomics overview

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc.

Frequently asked questions

What percentage of NeoGenomics is owned by insiders or institutions?
Currently 1.284% of NeoGenomics shares are held by insiders and 101.392% by institutions. How many people work for NeoGenomics?
Latest data suggests 2,100 work at NeoGenomics. When does the fiscal year end for NeoGenomics?
NeoGenomics's fiscal year ends in December. Where is NeoGenomics based?
NeoGenomics's address is: 9490 NeoGenomics Way, Fort Myers, FL, United States, 33912 What is NeoGenomics's ISIN number?
NeoGenomics's international securities identification number is: US64049M2098 What is NeoGenomics's CUSIP number?
NeoGenomics's Committee on Uniform Securities Identification Procedures number is: 64049M209